POSB49 Cost Effectiveness Model of Atezolizumab Plus Bevacizumab in Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) in French Setting
Abstract
Authors
C Dubois de Gennes B Mazaleyrat J Sanchez Alvarez B Lueza